Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

Chaput, Nathalie; Lepage, Patricia; Coutzac, Clélia; Soularue, Émilie; Roux, Karine Le; Monot, Céline; Boselli, Lisa; Routier, Émilie; Cassard, Lydie; Collins, Michael; Vaysse, Thibaut; Marthey, Lysiane; Eggermont, Alexander; Asvatourian, Vahé; Lanoy, Émilie; Mateus, Christine; Robert, Caroline; Carbonnel, Franck

doi:10.1093/annonc/mdx108

Cited by 929 publications

(682 citation statements)

References 42 publications

Supporting

Mentioning

650

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, the composition of gut microbiome was different between the two groups; Clostridiales were more abundant in responders however Bacteroidales were more frequent in nonresponders [8]. These findings were consistent with Chaput et al results concerning the possible adverse role of initial bacteroidetes colonization [7,8]. On the other hand, it has been demonstrated that tumor immune infiltrates including CD8 + T cells were increased in responders.…”

Section: For Reprint Orders Please Contact: Reprints@futuremedicinecomsupporting

confidence: 88%

“…Patients having microbiota enriched with Faecalibacterium genus and other Firmicutes had significantly higher progression-free survival (PFS) (p = 0.0039) and overall survival (OS) compared with patients having initial microbiota enriched with bacteroidetes. They also found higher proportion of these bacteria in all patients having overall survival longer than 18 months [7]. In contrast to Vetizou et al findings, patients who had poor clinical response to ipilimimuab presented higher representation of bacteroidetes (mostly bacteroidetes genus).…”

mentioning

confidence: 72%

“…In contrast to Vetizou et al findings, patients who had poor clinical response to ipilimimuab presented higher representation of bacteroidetes (mostly bacteroidetes genus). It can be attributed to a bias in the reconstitution of microbiota in mice using human fecal microbiota transplantation [5,7].Recent report evaluating the microbiome in patients treated with PD-1 inhibitors in metastatic melanoma showed that diversity and composition of gut microbiome was significantly different in patients responding to anti-PD-1 compared with those who do not respond. The diversity was significantly higher in responders versus…”

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Is Gut Microbiome A Predictive Marker to Response to Immune Checkpoint Inhibitors?

2017

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICI) are changing the treatment of solid and hematologic malignancies and becoming an integral part of the management of cancer patients. Ipilimumab, a CTLA-4 inhibitor, was associated with significant survival benefit in metastatic melanoma [1]. In addition, PD-1 and PD-L1 inhibitors such as nivolumab, pembrolizumab and atezolizumab showed remarkable clinical responses in multiple cancer types ranging from 20 to 30% when used in monotherapy. These agents are approved by the US FDA in the management of various tumor types such as metastatic melanoma, non-small-cell lung cancer (NSCLC), renal cell carcinoma, classical Hodgkin's lymphoma, urothelial bladder carcinoma and squamous cell carcinoma of the head and neck [2]. Identifying reliable biomarkers for efficacy would be of interest to improve the outcome and overcome resistance.Several candidate biomarkers had been explored including immunological ones such as intratumoral lymphoid infiltrates and intratumoral PD-L1 expression, genetic biomarkers like oncogenic mutations, mutational load and DNA-mismatch repair deficiency [3]. Recently, emerging data show that gut microbiome might affect the efficacy of ICI making it a potential biomarker of response. In addition, the manipulation of the microbiome by broad-spectrum antibiotics leads to increased susceptibility to infections, accumulation of antibiotic resistances, deregulated metabolism and compromised immune homeostasis [4].Recent reports focused on the role of microbiome in the response to ICI. It was first evaluated in murine models and preclinical studies showed the contribution of gut microbiome in the efficacy of ICI. Vetizou et al. demonstrated that tumor progression of sarcomas in mice housed in specific pathogen-free condition was inhibited with anti-CTLA-4 in contrast to mice housed in germ-free (GF) condition [5]. In addition, the use of broadspectrum antibiotics such as colistin and imipenem to eliminate gut microbiata altered the antitumor effect of CTLA-4 inhibitors. It was also confirmed in melanoma and colon cancer models. Moreover, the activation of splenic lymphocytes and tumor-infiltrating lymphocytes mediated by anti-CTLA-4 was significantly decreased in GF and antibiotic-treated mice [5]. When researchers recolonized GF mice and antibiotic-treated mice with bacterial species they found that anti-CTLA-4 anticancer responses could be restored with Bacteroides fragilis, Bacteroides thetaiotaomicron, Burkholderia cepacia, or the combination of B. fragilis and B. cepacia via stimulation of Th1 immune response [6].In a prospective study, 26 patients treated with ipilimumab for metastatic melanoma were enrolled. The authors found that anticancer response was associated with colonization by Firmicutes and specifically by Faecalibacterium prausnitzii L2-6, butyrate producing bacterium L2-21 and Gemmiger formicilis ATCC 27749. Patients having microbiota enriched with Faecalibacterium genus and other Firmicutes had significantly higher progression-free survival (PFS) (p ...

show abstract

Section: For Reprint Orders Please Contact: Reprints@futuremedicinecomsupporting

confidence: 88%

mentioning

confidence: 72%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Is Gut Microbiome A Predictive Marker to Response to Immune Checkpoint Inhibitors?

2017

View full text Add to dashboard Cite

show abstract

“…Some have proposed manipulation of gut microbiota prior to treatment administration to maximize therapeutic efficacy and minimize adverse effects. Fecal transplant is a recognized treatment for antibiotic refractory Clostridium difficile infections and may be utilized for patients undergoing checkpoint inhibitor therapy (11).…”

Section: Host Factors Of Response and Resistancementioning

confidence: 99%

Predictors of response and resistance to checkpoint inhibitors in solid tumors

Rao¹,

Moran²,

Graff³

2017

Ann. Transl. Med.

View full text Add to dashboard Cite

Effect of Azithromycin on Airflow Decline–Free Survival After Allogeneic Hematopoietic Stem Cell Transplant

Bergeron

Chevret

Granata

et al. 2017

JAMA

View full text Add to dashboard Cite

show abstract

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

Abstract: Baseline gut microbiota enriched with Faecalibacterium and other Firmicutes is associated with beneficial clinical response to ipilimumab and more frequent occurrence of ipilimumab-induced colitis.

Cited by 929 publications

References 42 publications

Is Gut Microbiome A Predictive Marker to Response to Immune Checkpoint Inhibitors?

Is Gut Microbiome A Predictive Marker to Response to Immune Checkpoint Inhibitors?

Predictors of response and resistance to checkpoint inhibitors in solid tumors

Effect of Azithromycin on Airflow Decline–Free Survival After Allogeneic Hematopoietic Stem Cell Transplant

Contact Info

Product

Resources

About